FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176479223> ?p ?o ?g. }

• W3176479223 endingPage "1009" @default.
• W3176479223 startingPage "999" @default.
• W3176479223 abstract "BackgroundConcurrent with the Pfizer–BioNTech BNT162b2 COVID-19 vaccine roll-out in Israel initiated on Dec 19, 2020, we assessed the early antibody responses and antibody kinetics after each vaccine dose in health-care workers of different ages and sexes, and with different comorbidities.MethodsWe did a prospective, single-centre, longitudinal cohort study at the Sheba Medical Centre (Tel-Hashomer, Israel). Eligible participants were health-care workers at the centre who had a negative anti-SARS-CoV-2 IgG assay before receiving the first dose of the intramuscular vaccine, and at least one serological antibody test after the first dose of the vaccine. Health-care workers with a positive SARS-CoV-2 PCR test before vaccination, a positive anti-SARS-CoV-2 IgG serology test before vaccination, or infection with COVID-19 after vaccination were excluded from the study. Participants were followed up weekly for 5 weeks after the first vaccine dose; a second dose was given at week 3. Serum samples were obtained at baseline and at each weekly follow-up, and antibodies were tested at 1–2 weeks after the first vaccine dose, at week 3 with the administration of the second vaccine dose, and at weeks 4–5 (ie, 1–2 weeks after the second vaccine dose). Participants with comorbidities were approached to participate in an enriched comorbidities subgroup, and at least two neutralising assays were done during the 5 weeks of follow-up in those individuals. IgG assays were done for the entire study population, whereas IgM, IgA, and neutralising antibody assays were done only in the enriched comorbidities subgroup. Concentrations of IgG greater than 0·62 sample-to-cutoff (s/co) ratio and of IgA greater than 1·1 s/co, and titres of neutralising antibodies greater than 10 were considered positive. Scatter plot and correlation analyses, logistic and linear regression analyses, and linear mixed models were used to investigate the longitudinal antibody responses.FindingsBetween Dec 19, 2020, and Jan 30, 2021, we obtained 4026 serum samples from 2607 eligible, vaccinated participants. 342 individuals were included in the enriched comorbidities subgroup. The first vaccine dose elicited positive IgG and neutralising antibody responses at week 3 in 707 (88·0%) of 803 individuals, and 264 (71·0%) of 372 individuals, respectively, which were rapidly increased at week 4 (ie, 1 week after the second vaccine dose) in 1011 (98·4%) of 1027 and 357 (96·5%) of 370 individuals, respectively. Over 4 weeks of follow-up after vaccination, a high correlation (r=0·92) was detected between IgG against the receptor-binding domain and neutralising antibody titres. First-dose induced IgG response was significantly lower in individuals aged 66 years and older (ratio of means 0·25, 95% CI 0·19–0·31) and immunosuppressed individuals (0·21, 0·14–0·31) compared with individuals aged 18·00–45·99 years and individuals with no immunosuppression, respectively. This disparity was partly abrogated following the second dose. Overall, endpoint regression analysis showed that lower antibody concentrations were consistently associated with male sex (ratio of means 0·84, 95% CI 0·80–0·89), older age (ie, ≥66 years; 0·64, 0·58–0·71), immunosuppression (0·44, 0·33–0·58), and other specific comorbidities: diabetes (0·88, 0·79–0·98), hypertension (0·90, 0·82–0·98), heart disease (0·86, 0·75–1·00), and autoimmune diseases (0·82, 0·73–0·92).InterpretationBNT162b2 vaccine induces a robust and rapid antibody response. The significant correlation between receptor-binding domain IgG antibodies and neutralisation titres suggests that IgG antibodies might serve as a correlate of neutralisation. The second vaccine dose is particularly important for older and immunosuppressed individuals, highlighting the need for timely second vaccinations and potentially a revaluation of the long gap between doses in some countries. Antibody responses were reduced in susceptible populations and therefore they might be more prone to breakthrough infections.FundingSheba Medical Center, Israel Ministry of Health." @default.
• W3176479223 created "2021-07-05" @default.
• W3176479223 creator A5001724117 @default.
• W3176479223 creator A5002704057 @default.
• W3176479223 creator A5004609370 @default.
• W3176479223 creator A5011801479 @default.
• W3176479223 creator A5013596025 @default.
• W3176479223 creator A5018804854 @default.
• W3176479223 creator A5031183927 @default.
• W3176479223 creator A5033290213 @default.
• W3176479223 creator A5047023960 @default.
• W3176479223 creator A5056325189 @default.
• W3176479223 creator A5068865686 @default.
• W3176479223 creator A5070745060 @default.
• W3176479223 creator A5080128827 @default.
• W3176479223 creator A5081851472 @default.
• W3176479223 creator A5085626163 @default.
• W3176479223 creator A5090111671 @default.
• W3176479223 date "2021-09-01" @default.
• W3176479223 modified "2023-10-14" @default.
• W3176479223 title "BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers" @default.
• W3176479223 cites W3002108456 @default.
• W3176479223 cites W3014294089 @default.
• W3176479223 cites W3031835167 @default.
• W3176479223 cites W3043671273 @default.
• W3176479223 cites W3048620154 @default.
• W3176479223 cites W3088593106 @default.
• W3176479223 cites W3090844627 @default.
• W3176479223 cites W3093367571 @default.
• W3176479223 cites W3108618259 @default.
• W3176479223 cites W3111255098 @default.
• W3176479223 cites W3111642148 @default.
• W3176479223 cites W3126729284 @default.
• W3176479223 cites W3131688063 @default.
• W3176479223 cites W3135210768 @default.
• W3176479223 doi "https://doi.org/10.1016/s2213-2600(21)00220-4" @default.
• W3176479223 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8253545" @default.
• W3176479223 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34224675" @default.
• W3176479223 hasPublicationYear "2021" @default.
• W3176479223 type Work @default.
• W3176479223 sameAs 3176479223 @default.
• W3176479223 citedByCount "251" @default.
• W3176479223 countsByYear W31764792232021 @default.
• W3176479223 countsByYear W31764792232022 @default.
• W3176479223 countsByYear W31764792232023 @default.
• W3176479223 crossrefType "journal-article" @default.
• W3176479223 hasAuthorship W3176479223A5001724117 @default.
• W3176479223 hasAuthorship W3176479223A5002704057 @default.
• W3176479223 hasAuthorship W3176479223A5004609370 @default.
• W3176479223 hasAuthorship W3176479223A5011801479 @default.
• W3176479223 hasAuthorship W3176479223A5013596025 @default.
• W3176479223 hasAuthorship W3176479223A5018804854 @default.
• W3176479223 hasAuthorship W3176479223A5031183927 @default.
• W3176479223 hasAuthorship W3176479223A5033290213 @default.
• W3176479223 hasAuthorship W3176479223A5047023960 @default.
• W3176479223 hasAuthorship W3176479223A5056325189 @default.
• W3176479223 hasAuthorship W3176479223A5068865686 @default.
• W3176479223 hasAuthorship W3176479223A5070745060 @default.
• W3176479223 hasAuthorship W3176479223A5080128827 @default.
• W3176479223 hasAuthorship W3176479223A5081851472 @default.
• W3176479223 hasAuthorship W3176479223A5085626163 @default.
• W3176479223 hasAuthorship W3176479223A5090111671 @default.
• W3176479223 hasBestOaLocation W31764792231 @default.
• W3176479223 hasConcept C126322002 @default.
• W3176479223 hasConcept C142724271 @default.
• W3176479223 hasConcept C159654299 @default.
• W3176479223 hasConcept C188816634 @default.
• W3176479223 hasConcept C201903717 @default.
• W3176479223 hasConcept C203014093 @default.
• W3176479223 hasConcept C22070199 @default.
• W3176479223 hasConcept C2777895361 @default.
• W3176479223 hasConcept C2908647359 @default.
• W3176479223 hasConcept C45189115 @default.
• W3176479223 hasConcept C71924100 @default.
• W3176479223 hasConcept C72563966 @default.
• W3176479223 hasConcept C99454951 @default.
• W3176479223 hasConceptScore W3176479223C126322002 @default.
• W3176479223 hasConceptScore W3176479223C142724271 @default.
• W3176479223 hasConceptScore W3176479223C159654299 @default.
• W3176479223 hasConceptScore W3176479223C188816634 @default.
• W3176479223 hasConceptScore W3176479223C201903717 @default.
• W3176479223 hasConceptScore W3176479223C203014093 @default.
• W3176479223 hasConceptScore W3176479223C22070199 @default.
• W3176479223 hasConceptScore W3176479223C2777895361 @default.
• W3176479223 hasConceptScore W3176479223C2908647359 @default.
• W3176479223 hasConceptScore W3176479223C45189115 @default.
• W3176479223 hasConceptScore W3176479223C71924100 @default.
• W3176479223 hasConceptScore W3176479223C72563966 @default.
• W3176479223 hasConceptScore W3176479223C99454951 @default.
• W3176479223 hasFunder F4320323944 @default.
• W3176479223 hasIssue "9" @default.
• W3176479223 hasLocation W31764792231 @default.
• W3176479223 hasLocation W31764792232 @default.
• W3176479223 hasOpenAccess W3176479223 @default.
• W3176479223 hasPrimaryLocation W31764792231 @default.
• W3176479223 hasRelatedWork W1525154324 @default.
• W3176479223 hasRelatedWork W2000783941 @default.
• W3176479223 hasRelatedWork W2030309204 @default.

• next